CUREVO, INC. | MedPath

Curevo Secures $110 Million Series B Funding to Advance Next-Generation Shingles Vaccine

2 months ago

• Curevo's shingles vaccine candidate amezosvatein has demonstrated strong immunogenicity with improved tolerability in Phase 2 studies, positioning it as a potential alternative to current market options. • The $110 million Series B funding round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, Sanofi Ventures, and existing investors to support extended Phase 2 trials in adults over 70. • Former Operation Warp Speed Chief Scientific Advisor and GSK vaccine executive Moncef Slaoui joins Curevo as Board Chair, bringing significant vaccine development expertise to the company.

AstraZeneca Acquires European Cell Therapy Biotech in Deal Worth Up to $1 Billion

2 months ago

• AstraZeneca has expanded its cell therapy portfolio by acquiring a European biotech company in a deal valued at up to $1 billion, strengthening its position in the advanced therapeutics market. • The acquisition provides AstraZeneca immediate access to novel cell therapy technologies and an expanded pipeline of candidates, potentially accelerating development timelines for new therapeutic options. • Industry analysts view this strategic move as part of AstraZeneca's broader initiative to diversify beyond traditional pharmaceuticals into cutting-edge cellular therapies with significant growth potential.

Curevo's Amezosvatein Shows Sustained Immunogenicity and Improved Tolerability in Phase 2 Shingles Vaccine Trial

4 months ago

• Curevo's amezosvatein maintained non-inferior anti-gE antibody levels compared to Shingrix one year after the second dose in adults aged 50-69. • The Phase 2 trial (NCT05304351) demonstrated that amezosvatein had a statistically significant improvement in Grade 2 and 3 reactogenicity versus Shingrix. • No confirmed shingles cases were observed in the highest antigen dose arms of amezosvatein or the Shingrix arm during the post-hoc analysis. • Curevo plans to advance amezosvatein into global Phase 3 trials in 2025, targeting the multi-billion dollar shingles vaccine market.

Curevo Vaccine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

5 months ago

Curevo Vaccine, a clinical-stage biotechnology company, will present updated data from its 876-patient trial of amezosvatein, a shingles vaccine, at the 43rd Annual J.P. Morgan Healthcare Conference.

Curevo's Amezosvatein Shows Zero Shingles Cases in Phase 2 Trial

7 months ago

• Curevo's amezosvatein vaccine demonstrated zero confirmed cases of shingles in a Phase 2 trial after 18.8 months of follow-up, contrasting with an expected 10 cases without vaccination. • The Phase 2 trial (NCT05304351) compared amezosvatein head-to-head against Shingrix in 876 participants aged 50 and older, showing comparable safety profiles between the two vaccines. • Amezosvatein exhibited a statistically significant improvement in Grade 2 and Grade 3 reactogenicity compared to Shingrix, potentially improving vaccine accessibility and reducing hesitancy. • The highest dose of amezosvatein met the co-primary immunogenicity endpoint, demonstrating non-inferior immune responses to Shingrix, with similar serum neutralizing antibodies to VZV.

Curevo's Amezosvatein Shows Promise in Phase 2 Trial with Improved Tolerability for Shingles Vaccine

a year ago

• Curevo Vaccine's amezosvatein demonstrated non-inferiority to Shingrix in a Phase 2 trial, meeting all primary endpoints for immunogenicity. • The trial, involving 876 participants, showed amezosvatein had a 100% vaccine response rate compared to Shingrix's 97.9%. • Amezosvatein exhibited lower rates of local and systemic adverse events, suggesting improved tolerability over the existing Shingrix vaccine. • Curevo plans to advance amezosvatein into global Phase 3 trials in 2024, targeting the $4 billion shingles vaccine market.